What Is SR-17018? Complete Guide to G Protein-Biased Kappa Opioid Agonists

The Search for Safer Kappa Opioid Receptor Modulation

For decades, researchers have recognized the therapeutic potential of the kappa opioid receptor (KOR) system while struggling with its challenging pharmacology. Traditional KOR agonists produce powerful analgesic and anti-pruritic effects but also trigger dysphoria, sedation, and psychotomimetic effects that limit their clinical utility.

SR-17018 represents a breakthrough in this pursuit. As a G protein-biased kappa opioid agonist, this research compound demonstrates remarkable selectivity for the signaling pathways associated with beneficial effects while minimizing activation of pathways linked to adverse outcomes.

This comprehensive guide examines SR-17018 from multiple angles: its molecular mechanism, the science of biased agonism, practical research applications, and essential handling specifications. Whether you are designing new protocols or evaluating compounds for your laboratory, understanding SR-17018's unique pharmacological profile is essential.

TL;DR: SR-17018 at a Glance

What it is: SR-17018 is a highly selective G protein-biased agonist at the kappa opioid receptor (KOR), designed to preferentially activate G protein signaling over beta-arrestin recruitment.
Key advantage: Preclinical studies demonstrate that G protein-biased KOR agonists like SR-17018 may produce analgesic and anti-pruritic effects with reduced dysphoria and sedation compared to unbiased agonists.
Mechanism: SR-17018 binds to the orthosteric site of the kappa opioid receptor and stabilizes receptor conformations that favor Gi/o protein coupling while minimizing beta-arrestin recruitment.
Research value: This compound serves as an essential pharmacological tool for dissecting KOR signaling pathways and testing the biased agonism hypothesis in various experimental models.
Availability: High-purity SR-17018 is available for research purchase in quantities suitable for both in vitro and in vivo studies.

What Is SR-17018?

SR-17018 is a synthetic small molecule that acts as a potent and selective agonist at the kappa opioid receptor (KOR, also designated OPRK1). What distinguishes SR-17018 from classical KOR agonists is its biased agonism profile: it preferentially activates G protein-mediated signaling pathways while demonstrating markedly reduced efficacy for beta-arrestin recruitment.

Chemical Identity and Classification

SR-17018 belongs to a class of compounds developed specifically to test the hypothesis that separating G protein signaling from beta-arrestin recruitment at the kappa opioid receptor could yield improved pharmacological profiles. It was designed and characterized by research groups investigating structure-activity relationships among biased opioid ligands.

The compound is classified as:

A kappa opioid receptor agonist (KOR agonist, OPRK1 agonist)
A G protein-biased ligand (Gi/o-biased)
A beta-arrestin-sparing agonist
A functionally selective opioid

Historical Context

The development of SR-17018 emerged from extensive research into the "biased agonism hypothesis" at opioid receptors. This hypothesis proposes that the beneficial analgesic and anti-pruritic effects of KOR activation are mediated primarily through G protein signaling, while adverse effects such as dysphoria, sedation, and aversion are driven substantially by beta-arrestin-dependent pathways.

Early proof-of-concept studies with other biased ligands demonstrated that it was chemically feasible to create KOR agonists with varying degrees of bias. SR-17018 emerged as a tool compound with a particularly clean pharmacological profile for research applications, offering researchers a way to study KOR-mediated analgesia without the confounding effects of dysphoria.

How Does SR-17018 Work?

Understanding SR-17018's mechanism requires examining the molecular events that occur when any ligand binds to the kappa opioid receptor. The KOR is a G protein-coupled receptor (GPCR) that can activate multiple downstream signaling cascades depending on the specific ligand that binds to it.

The Kappa Opioid Receptor: A Two-Pathway System

When a classical full agonist like U50,488 or salvinorin A binds to the KOR, it triggers two major intracellular signaling cascades:

Pathway 1: G Protein Signaling (Gi/o)

The activated receptor couples to inhibitory G proteins (Gi and Go)
This leads to inhibition of adenylyl cyclase and reduced cAMP production
Downstream effects include neuronal hyperpolarization, reduced neurotransmitter release, and analgesia
This pathway is generally associated with the therapeutic effects: pain relief, anti-itch, and anti-addiction properties

Pathway 2: Beta-Arrestin Recruitment

Following G protein activation, G protein-coupled receptor kinases (GRKs) phosphorylate the receptor
Beta-arrestin proteins are recruited to the phosphorylated receptor
This initiates receptor internalization and additional signaling cascades
Research has linked this pathway to dysphoria, aversion, sedation, and stress responses

SR-17018's Biased Mechanism

SR-17018 binds to the same orthosteric binding pocket on the KOR as classical kappa agonists. However, the specific molecular interactions between SR-17018 and the receptor stabilize a unique receptor conformation.

This conformation efficiently couples to Gi/o proteins but adopts a geometry that is suboptimal for GRK-mediated phosphorylation and subsequent beta-arrestin recruitment. The result is functional selectivity: SR-17018 activates one signaling arm of the receptor while minimizing activation of the other.

Quantifying Bias: The Bias Factor

Researchers quantify biased agonism using "bias factors" calculated from operational model analyses. These values compare a compound's relative efficacy for G protein signaling versus beta-arrestin recruitment, normalized to a reference agonist.

SR-17018 demonstrates substantial G protein bias, with published bias factors indicating preferential G protein signaling over beta-arrestin recruitment. In standard GTPgammaS binding and cAMP accumulation assays, SR-17018 functions as a full agonist. In contrast, beta-arrestin recruitment assays typically show markedly reduced efficacy.

Receptor Binding Profile

SR-17018 exhibits high affinity for the kappa opioid receptor with excellent selectivity over mu (MOR) and delta (DOR) opioid receptor subtypes. This selectivity is crucial: it means SR-17018 produces its effects without engaging the reward pathways associated with mu opioid receptors, making it a valuable tool for addiction research.

Why Biased Agonism Matters for KOR Research

The concept of biased agonism has transformed how researchers approach GPCR pharmacology. For the kappa opioid receptor specifically, biased agonism offers a potential solution to one of pharmacology's most persistent challenges: harnessing KOR's therapeutic potential while avoiding its aversive effects.

The Traditional KOR Agonist Problem

Classical KOR agonists produce powerful therapeutic effects but are limited by:

Dysphoria and negative mood states
Sedation and motor impairment
Psychotomimetic effects at higher doses
Aversion that limits patient compliance
Stress-like responses in preclinical models

These effects have prevented KOR agonists from achieving widespread clinical use despite their promising analgesic, anti-pruritic, and anti-addiction properties.

The Beta-Arrestin Hypothesis at KOR

Research has suggested that the aversive effects of KOR activation may be mediated substantially through beta-arrestin-dependent signaling cascades. Studies comparing G protein-biased versus unbiased KOR agonists have shown that bias toward G protein signaling correlates with reduced aversion in preclinical models.

If a drug could activate G protein signaling without recruiting beta-arrestin, it might produce "cleaner" analgesia and anti-pruritic effects without the dysphoric burden.

Observed Effects in SR-17018 Studies

Preclinical research with SR-17018 and related G protein-biased KOR agonists has generated compelling data supporting the biased agonism hypothesis:

Reduced Aversion

Studies comparing SR-17018 to unbiased KOR agonists in conditioned place preference paradigms have demonstrated that G protein-biased agonists produce significantly less aversion at equi-analgesic doses.

Maintained Analgesia

Despite reduced arrestin signaling, SR-17018 retains robust analgesic efficacy in multiple pain models, supporting the hypothesis that G protein signaling is sufficient for KOR-mediated analgesia.

Anti-Pruritic Effects

KOR agonists are potent anti-itch agents. SR-17018 studies have explored whether biased agonism can separate anti-pruritic efficacy from sedative effects.

Scientific Debate and Ongoing Research

It is important to note that the biased agonism hypothesis remains an active area of scientific investigation. The precise contributions of different signaling pathways to KOR's diverse effects continue to be studied.

SR-17018 serves as a valuable tool for testing these hypotheses. Its clean pharmacological profile allows researchers to isolate the contributions of G protein versus arrestin signaling in various experimental contexts.

Key Research Applications

SR-17018 has become an essential pharmacological tool across multiple research domains. Its well-characterized bias profile makes it valuable for both basic mechanistic studies and translational research programs.

Receptor Signaling Studies

Researchers use SR-17018 in cell-based assays to:

Characterize the structural determinants of biased agonism at the KOR
Map the intracellular signaling cascades downstream of G protein versus beta-arrestin pathways
Validate assay systems for screening novel biased ligands
Investigate receptor conformational dynamics using biophysical techniques

Pain and Analgesia Research

In preclinical pain models, SR-17018 enables researchers to:

Compare analgesic efficacy between biased and unbiased KOR agonists
Evaluate the relationship between bias factor and therapeutic index
Study KOR-mediated analgesia independent of mu opioid pathways
Investigate potential for non-addictive pain therapeutics

Addiction and Reward Research

KOR activation can block reward from drugs of abuse. SR-17018 serves as a tool for studying:

KOR modulation of dopaminergic reward circuits
Anti-addiction effects without dysphoria
Potential therapeutic approaches for substance use disorders
The role of beta-arrestin in stress and aversion responses

Pruritus Research

KOR agonists are among the most effective anti-itch agents. SR-17018 enables:

Study of KOR-mediated anti-pruritic mechanisms
Development of itch therapeutics with reduced sedation
Investigation of peripheral versus central KOR effects

Drug Development Tool Compound

Pharmaceutical researchers employ SR-17018 as:

A reference compound for validating bias quantification methodologies
A benchmark for comparing novel lead compounds
A positive control in high-throughput screening campaigns

SR-17018 Specifications

The following specifications represent typical values for research-grade SR-17018. Researchers should consult the Certificate of Analysis (CoA) for lot-specific data.

Parameter	Specification
Chemical Name	SR-17018
CAS Number	1421249-69-5
Molecular Formula	C24H28N2O2
Molecular Weight	376.49 g/mol
Physical Form	White to off-white powder
Purity	Greater than or equal to 99% (HPLC)
Solubility	Soluble in DMSO; limited aqueous solubility
Storage Temperature	-20 degrees Celsius (desiccated)
Stability	Stable for 2 years when stored properly

Pharmacological Parameters

Assay	Value	Notes
KOR Binding Affinity (Ki)	Low nanomolar range	Radioligand displacement
G Protein EC50	Nanomolar range	Full agonist efficacy
Beta-Arrestin Recruitment	Minimal to undetectable	PathHunter or BRET assays
Bias Factor	Strongly G protein-biased	Relative to reference agonists
MOR Selectivity	High selectivity over MOR	KOR-selective
DOR Selectivity	High selectivity over DOR	KOR-selective

High-purity SR-17018 for research applications is available in our online shop.

Handling and Storage

Proper handling and storage of SR-17018 ensures compound integrity and experimental reproducibility. The following guidelines are recommended for research laboratories.

Storage Conditions

Temperature: Store at -20 degrees Celsius for long-term stability
Environment: Keep in a desiccated environment to prevent moisture absorption
Light protection: Store in amber vials or protect from prolonged light exposure
Container: Use airtight containers with appropriate seals

Solution Preparation

SR-17018 demonstrates limited aqueous solubility. For most applications:

Prepare concentrated stock solutions in DMSO (10-50 mM stocks are typical)
Dilute into aqueous buffers immediately before use
Final DMSO concentration should not exceed 0.1-1% for cell-based assays
For in vivo studies, common vehicles include DMSO/Tween-80/saline formulations

Stability Considerations

DMSO stock solutions may be stored at -20 degrees Celsius for several months
Avoid repeated freeze-thaw cycles; aliquot stocks upon preparation
Aqueous dilutions should be prepared fresh for each experiment
Monitor for precipitation when diluting into aqueous media

Safety Handling

Handle as a pharmacologically active compound
Use appropriate personal protective equipment (gloves, lab coat, eye protection)
Work in well-ventilated areas or fume hoods when handling powder
Dispose of waste according to institutional guidelines for pharmaceutical compounds

Frequently Asked Questions

What is the difference between SR-17018 and traditional KOR agonists?

SR-17018 and traditional KOR agonists like U50,488 or salvinorin A differ fundamentally in their signaling profiles. Traditional agonists are unbiased, activating both G protein and beta-arrestin pathways robustly. SR-17018 is a G protein-biased agonist that preferentially activates G protein signaling while minimizing beta-arrestin recruitment. In preclinical models, this translates to analgesic effects with potentially reduced dysphoria and aversion for SR-17018 compared to unbiased agonists.

Why is KOR selectivity important?

KOR selectivity means SR-17018 does not activate mu opioid receptors, which are responsible for the rewarding and addictive effects of drugs like morphine and fentanyl. This makes SR-17018 a valuable tool for studying pain relief and anti-addiction mechanisms without engaging reward pathways. It also means there is no risk of the respiratory depression associated with mu agonists.

What concentrations of SR-17018 are used in research?

Appropriate concentrations depend on the specific application. For in vitro receptor binding and functional assays, concentrations typically range from 0.1 nM to 10 micromolar. For cellular assays examining signaling, 1-1000 nM concentration ranges are common. For in vivo studies in rodent models, researchers should consult the literature for appropriate dosing in their specific experimental systems.

How do I prepare SR-17018 solutions for experiments?

Due to limited aqueous solubility, SR-17018 should first be dissolved in DMSO to create a concentrated stock solution (commonly 10-50 mM). This stock can be stored at -20 degrees Celsius in aliquots. For working solutions, dilute the DMSO stock into your assay buffer immediately before use, ensuring the final DMSO concentration remains below levels that affect your experimental system (typically less than 0.1-1% for cell-based assays).

What is a bias factor and why does it matter?

A bias factor is a quantitative measure that compares a ligand's relative efficacy for activating one signaling pathway versus another. For opioid receptors, bias factors typically compare G protein activation to beta-arrestin recruitment. A bias factor toward G protein indicates preferential G protein signaling. SR-17018 demonstrates strong G protein bias. This metric matters because it predicts the pharmacological profile of the compound and allows researchers to correlate bias with functional outcomes in preclinical models.

References

Brust TF, Morgenweck J, Kim SA, et al. Biased agonists of the kappa opioid receptor suppress pain and itch without causing sedation or dysphoria. Sci Signal. 2016;9(456):ra117.
White KL, Robinson JE, Zhu H, et al. The G protein-biased kappa-opioid receptor agonist RB-64 is analgesic with a unique spectrum of activities in vivo. J Pharmacol Exp Ther. 2015;352(1):98-109.
Roth BL, Baner K, Bhargava R, et al. Salvinorin A: a potent naturally occurring nonnitrogenous kappa opioid selective agonist. Proc Natl Acad Sci USA. 2002;99(18):11934-11939.
Chavkin C, Koob GF. Dynorphin, Dysphoria, and Dependence: the Stress of Addiction. Neuropsychopharmacology. 2016;41(1):373-374.
Schattauer SS, Kuhar JR, Song A, Bhargava R. Ligand-directed signaling differences between rodent and human kappa-opioid receptors. J Biol Chem. 2017;292(27):11121-11136.

For research use only. Not for human consumption.

Ready to advance your kappa opioid receptor research? Browse our SR-17018 products or visit our complete catalog of research compounds.

Conducting your own research?